Literature DB >> 36109442

Sustained inhibition of CC-chemokine receptor-2 via intraarticular deposition of polymeric microplates in post-traumatic osteoarthritis.

Huseyin Ozkan1, Martina Di Francesco2, Helen Willcockson1, José Valdés-Fernández1,3, Valentina Di Francesco2, Froilán Granero-Moltó3,4,5,6, Felipe Prósper3,5,6,7,8, Paolo Decuzzi2, Lara Longobardi9.   

Abstract

Posttraumatic osteoarthritis (PTOA) is mostly treated via corticosteroid administration, and total joint arthroplasty continues to be the sole effective intervention in severe conditions. To assess the therapeutic potential of CCR2 targeting in PTOA, we used biodegradable microplates (µPLs) to achieve a slow and sustained intraarticular release of the CCR2 inhibitor RS504393 into injured knees and followed joint damage during disease progression. RS504393-loaded µPLs (RS-µPLs) were fabricated via a template-replica molding technique. A mixture of poly(lactic-co-glycolic acid) (PLGA) and RS504393 was deposited into 20 × 10 μm (length × height) wells in a polyvinyl alcohol (PVA) square-patterned template. After physicochemical and toxicological characterizations, the RS504393 release profile from µPL was assessed in PBS buffer. C57BL/6 J male mice were subjected to destabilization of the medial meniscus (DMM)/sham surgery, and RS-µPLs (1 mg/kg) were administered intraarticularly 1 week postsurgery. Administrations were repeated at 4 and 7 weeks post-DMM. Drug free-µPLs (DF-µPLs) and saline injections were performed as controls. Mice were euthanized at 4 and 10 weeks post-DMM, corresponding to the early and severe PTOA stages, respectively. Knees were evaluated for cartilage structure score (ACS, H&E), matrix loss (safranin O score), osteophyte formation and maturation from cartilage to bone (cartilage quantification), and subchondral plate thickness. The RS-µPL architecture ensured the sustained release of CCR2 inhibitors over several weeks, with ~ 20% of RS504393 still available at 21 days. This prolonged release improved cartilage structure and reduced bone damage and synovial hyperplasia at both PTOA stages. Extracellular matrix loss was also attenuated, although with less efficacy. The results indicate that local sustained delivery is needed to optimize CCR2-targeted therapies.
© 2022. The Author(s).

Entities:  

Keywords:  Chemokines; Local drug delivery; Murine osteoarthritis model; Osteoarthritis; Polymeric microparticles

Year:  2022        PMID: 36109442     DOI: 10.1007/s13346-022-01235-1

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   5.671


  37 in total

1.  Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials.

Authors:  Jinying Lin; Weiya Zhang; Adrian Jones; Michael Doherty
Journal:  BMJ       Date:  2004-07-30

2.  Role of the C-C chemokine receptor-2 in a murine model of injury-induced osteoarthritis.

Authors:  L Longobardi; J D Temple; L Tagliafierro; H Willcockson; A Esposito; N D'Onofrio; E Stein; T Li; T J Myers; H Ozkan; M L Balestrieri; V Ulici; R F Loeser; A Spagnoli
Journal:  Osteoarthritis Cartilage       Date:  2016-11-14       Impact factor: 6.576

3.  Reduction in disease progression by inhibition of transforming growth factor α-CCL2 signaling in experimental posttraumatic osteoarthritis.

Authors:  C Thomas G Appleton; Shirine E Usmani; Michael A Pest; Vasek Pitelka; John S Mort; Frank Beier
Journal:  Arthritis Rheumatol       Date:  2015-10       Impact factor: 10.995

4.  Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease.

Authors:  Thomas D Brown; Richard C Johnston; Charles L Saltzman; J Lawrence Marsh; Joseph A Buckwalter
Journal:  J Orthop Trauma       Date:  2006 Nov-Dec       Impact factor: 2.512

5.  Clinical and molecular associations with outcomes at 2 years after acute knee injury: a longitudinal study in the Knee Injury Cohort at the Kennedy (KICK).

Authors:  Cesar Garriga; Megan Goff; Erin Paterson; Renata Hrusecka; Benjamin Hamid; Jennifer Alderson; Kirsten Leyland; Lesley Honeyfield; Liam Greenshields; Keshthra Satchithananda; Adrian Lim; Nigel K Arden; Andrew Judge; Andrew Williams; Tonia L Vincent; Fiona E Watt
Journal:  Lancet Rheumatol       Date:  2021-06-24

6.  Associations between the chemokine biomarker CCL2 and knee osteoarthritis outcomes: the Johnston County Osteoarthritis Project.

Authors:  L Longobardi; J M Jordan; X A Shi; J B Renner; T A Schwartz; A E Nelson; D A Barrow; V B Kraus; A Spagnoli
Journal:  Osteoarthritis Cartilage       Date:  2018-05-01       Impact factor: 6.576

7.  CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis.

Authors:  Harini Raghu; Christin M Lepus; Qian Wang; Heidi H Wong; Nithya Lingampalli; Francesca Oliviero; Leonardo Punzi; Nicholas J Giori; Stuart B Goodman; Constance R Chu; Jeremy B Sokolove; William H Robinson
Journal:  Ann Rheum Dis       Date:  2016-12-13       Impact factor: 19.103

8.  Serum and synovial fluid chemokine ligand 2/monocyte chemoattractant protein 1 concentrations correlates with symptomatic severity in patients with knee osteoarthritis.

Authors:  Liang Li; Bao-En Jiang
Journal:  Ann Clin Biochem       Date:  2014-07-08       Impact factor: 2.057

9.  Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural and functional homologue of human MCP-1.

Authors:  M N Sarafi; E A Garcia-Zepeda; J A MacLean; I F Charo; A D Luster
Journal:  J Exp Med       Date:  1997-01-06       Impact factor: 14.307

10.  Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys.

Authors:  Jean-Pierre Pelletier; Johanne Martel-Pelletier; François Rannou; Cyrus Cooper
Journal:  Semin Arthritis Rheum       Date:  2015-12-02       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.